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 In this issue of  Kidney International , Zhang 
 et al. 1 report a carefully performed study 
in which they addressed the important 
question of the role of mitochondria-
related oxidative stress in the development 
of hypertension. Th ey show that the mito-
chondrial respiratory chain complex I 
inhibitor rotenone signifi cantly attenuated 
deoxycorticosterone acetate (DOCA)-salt-
induced hypertension and urinary 8-iso-
prostane excretion, and reduced reactive 
oxygen species production in isolated kid-
ney mitochondria. Other mitochondrial 
inhibitors, including 5-hydroxydecanoate, 
a mitochondrial ATP-sensitive potassium 
channel inhibitor; benzylguanidine, an 
inhibitor of complexes I and III; and man-
ganese tetrakis (4-benzoic acid) porphy-
rin, an antioxidant, similarly attenuated 
DOCA-salt-induced hypertension. In 
contrast, mice deficient in gp91 phox or 
p47 phox , both subunits of NAD(P)H oxi-
dase, exhibited only a partial attenuation 
of hypertension at early stages following 
the DOCA-salt treatment. Th e authors 
conclude that the mitochondrial respira-
tory chain, not NAD(P)H oxidase, is a 
major source of oxidative stress in mice 
with DOCA-salt-induced hypertension. 
 Th e study provides further support for 
the increasing recognition that mitochon-
dria-related oxidative stress contributes to 
the development of hypertension. Hyper-
tension in several animal models has been 
shown to be attenuated by inhibition of 
mitochondrial generation of reactive oxy-
gen species or elevation of the antioxida-
tive capacity of mitochondria. For example, 
administration of mitoTEMPO 2 or 
MitoQ10 3 or overexpression of the mito-
chondrial superoxide dismutase SOD2 2 or 
the thioredoxin TXN2 4 has been reported 
to attenuate angiotensin II-induced hyper-
tension in mice or the development of 
hypertension in the  spontaneous hyper-
tensive rat. Conversely, tissue-specific 
hypermethylation of the  Sod2 gene was 
associated with pulmonary arterial 
 hypertension in the fawn-hooded rat com-
pared with a protected consomic strain. 5 
Gene hypermethylation is oft en associated 
with transcriptional inhibition. In addi-
tion, knock-down of uncoupling protein 2 
potentiated oxidative stress and hyperten-
sion induced by intracerebroventricular 
infusion of angiotensin II. 6 Uncoupling 
protein 2 can mitigate mitochondrial pro-
duction of reactive oxygen species. 
 Mitochondria represent one of several 
possible sources of cellular reactive oxy-
gen species. Th e relative importance of 
various sources of reactive oxygen species 
to the development of hypertension is 
oft en not clear. Th e study by Zhang  et al. 1 
suggests that NAD(P)H oxidase is of lim-
ited importance in the development of 
hypertension in the DOCA-salt model. As 
the authors acknowledge, it is not entirely 
clear why their current findings differ 
from those of previous studies that have 
reported important roles of NAD(P)H 
oxidase subunits in this model of hyper-
tension. Th e authors emphasize that the 
methods of blood pressure measurement 
were diff erent among the studies. Th eir 
current study used radiotelemetry. Mito-
chondria and NAD(P)H oxidase may not 
be mutually exclusive sources of reactive 
oxygen species aft er all. Reactive oxygen 
species generated from one source could 
stimulate the production from another 
source, as discussed by Zhang  et al. 1 
 A key question is the relationship 
between initiating causes of hypertension 
and mitochondria-related oxidative stress. 
In the DOCA-salt model, the treatment 
(DOCA and increased salt intake) may 
induce mitochondrial oxidative stress, 
which then contributes to the develop-
ment of hypertension. Alternatively, the 
treatment may initiate the development of 
hypertension, leading to secondary mito-
chondrial oxidative stress, which then 
exacerbates hypertension. In complex 
genetic models of hypertension such as 
the Dahl salt-sensitive (SS) rat, oxidative 
stress could be in part genetically deter-
mined and present prior to a high-salt 
challenge. Increased salt intake may 
worsen oxidative stress or interact with 
existing oxidative stress in other ways, 
leading to the rapid and progressive 
increase in arterial blood pressure 
observed in the SS rat. 
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 Recent, exciting evidence suggests that 
abnormalities in cellular metabolism 
could be linked to hypertension and that 
oxidative stress could have a role in that 
link. It has been nearly six decades since 
Hans Krebs received the Nobel Prize for 
his discovery of the tricarboxylic acid 
(TCA) cycle. Cellular metabolism in or 
outside of mitochondria, however, is oft en 
considered obligatory and, therefore, 
unlikely to alter regulatory mechanisms 
or contribute to the development of com-
plex diseases such as hypertension. Th at 
perception is beginning to change. 7 For 
example, a proteomic study revealed dra-
matic diff erences in fumarase, an enzyme 
in the TCA cycle, between the SS rat and its 
protected control rat strain. 8 Subsequent 
sequencing, biochemical, and physiologi-
cal analyses indicated a sequence variant 
in the fumarase gene and suggested that 
higher fumarase activities found in the 
protected rat strain could attenuate oxida-
tive stress and contribute to the protection 
from salt-induced hypertension. 9 Excess 
of succinate, upstream from fumaric acid 
in the TCA cycle, has also been shown to 
cause hypertension in mice. 10 It 
is not known whether oxidative stress 
plays a role in the hypertensive eff ect of 
succinate excess. 
 Oxidative stress is not the only mecha-
nism that could mediate hypertensive 
effects of metabolic or mitochondrial 
disorders. Accumulation of several TCA 
cycle intermediates could result in a 
 pseudohypoxic state that leads to activa-
tion of hypoxia-inducible factors, includ-
ing HIF1  , a culprit in the development 
of pulmonary arterial hypertension. In 
addition, mutations in a mitochondrial 
transfer RNA have been linked to human 
hypertension and other metabolic defects. 11 
In the current study by Zhang  et al. , 1 none 
of the inhibitors used was a specifi c inhib-
itor of mitochondrial oxidative stress. Th e 
authors report that the inhibitors did not 
result in overt toxicity. However, interfer-
ence of the electron transport chain could 
have a variety of subtle eff ects on cellular 
functions that might eventually affect 
blood pressure. Th e physiological mecha-
nism mediating the antihypertensive 
eff ects of the inhibitors used by Zhang 
 et al. 1 remains to be elucidated. 
 A possible role of mitochondrial and 
cellular metabolic abnormalities in the 
development of hypertension is exciting. 
It opens up a host of pathways that could 
eventually explain the ultimate cause of 
hypertension rooted in lifestyle choices 
and developmental and aging processes, 
all of which are closely related to cellular 
metabolism ( Figure 1 ). Th e etiology and 
the molecular pathophysiology of hyper-
tension are probably like a jigsaw puzzle 
of diff erent but overlapping sets of fac-
tors and pathways that vary from one 
patient or one group of patients to 
another. Mitochondrial and metabolic 
abnormalities could be crucial pieces of 
this puzzle. 
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 Figure 1  |  Mitochondrial and metabolic abnormalities could play an important role in the 
pathophysiology of hypertension. 
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